Roche

Employees 2013: 85,080
Employees 2012: 82,089
% Change: +3.64
Revenues 2013: $52.31 billion
Revenues per employee: $614,797

Although there were some definite hiccups, Roche ($RHHBY) came out of 2013 a happy camper. The company hired nearly 3,000 new employees. While Roche is on the lower end of this list, it had the second highest employee hiring numbers, coming in right after Novartis ($NVS). And even though it added people, its revenue per employee was the second best on the list, behind only Pfizer ($PFE), which got there by cutting people.

The Swiss drugmaker grew thanks to a strong year of sales. Its revenue grew 9.43% in 2013. Cancer drugs Herceptin, Avastin and Xeloda, age-related macular degeneration drug Lucentis and rheumatoid arthritis drug Actemra led the drug sales.

Roche hit some roadblocks, pulling the plug on diabetes drug aleglitazar, once tapped as a blockbuster hopeful. Then its successful R&D chief, Hal Barron, left for a new position at Google ($GOOG). Sandra Horning, previous head of clinical development of oncology and hematology, took over Barron's position.

For more:
Roche highlights strong 2013 sales of cancer, vows to boost dividend
Post-reform Roche stumbles as top schizophrenia drug fizzles in PhIII

Roche
Read more on

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.